RESEARCH

Split Viewer

Blood Res (2024) 59:19

Published online May 14, 2024

https://doi.org/10.1007/s44313-024-00018-6

© The Korean Society of Hematology

Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis

Deepika Gupta1, Vandana Arya1, Jasmita Dass2, Nitin Gupta1, Manas Kalra3, Anupam Sachdeva3 and Jyoti Kotwal1*

1Department of Hematology, Sir Gangaram Hospital, Old Rajinder Nagar, New Delhi 110060, India. 2Department of Lab Hematology, All India Institute of Medical Sciences, New Delhi, India. 3Department of Pediatric Hemato Oncology, Sir Gangaram Hospital, New Delhi, India.

Correspondence to : *Jyoti Kotwal
drjyotikotwal@gmail.com

Part of the of data was presented as a poster at a national conference in 2022.

Received: October 21, 2023; Accepted: April 1, 2024

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Background Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by reduced factor VIII (FVIII) levels. Approximately 10–15% of patients with severe HA (SHA) do not present with the anticipated bleeding pattern. Here, we assessed the phenotypic severity of hemophilia A using rotational thromboelastometry (ROTEM) and activated partial thromboplastin time-clot waveform analysis (APTT-CWA).
Methods Patients diagnosed with hemophilia A were enrolled. Clinical phenotype assignment was performed according to the published literature, and patients were classified into four phenotypic subgroups. The whole blood sample was first run on ROTEM in INTEM mode using platelet-poor plasma, APTT was run, and the APTT-CWA graph was simultaneously recorded.
Results A total of 66 patients were recruited for this study. Statistically significant differences were observed between the four phenotypically categorized groups using ROTEM and APTT-CWA. On comparing patients with mild/moderate-to-severe phenotypes (Group II) with SHA without inhibitors (Group IV), no significant difference was found for all parameters of ROTEM or APTT-CWA. The MCF, MA30, MAXV, and Alpha angle values using ROTEM were found to be the lowest in patients with SHA with inhibitors, which helped differentiate them from those with SHA without inhibitors. However, these two groups could not be differentiated using the APTT-CWA parameters.
Conclusion ROTEM can be used to distinguish patients with SHA with inhibitors from those with SHA without inhibitors using a combination of parameters with high sensitivity and specificity. However, APTT-CWA cannot be used to differentiate these patient groups.


Keywords: Hemophilia A, ROTEM, APTT-CWA , Phenotype severity, Bleeding disorder, Bethesda assay

Article

RESEARCH

Blood Res 2024; 59():

Published online May 14, 2024 https://doi.org/10.1007/s44313-024-00018-6

Copyright © The Korean Society of Hematology.

Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis

Deepika Gupta1, Vandana Arya1, Jasmita Dass2, Nitin Gupta1, Manas Kalra3, Anupam Sachdeva3 and Jyoti Kotwal1*

1Department of Hematology, Sir Gangaram Hospital, Old Rajinder Nagar, New Delhi 110060, India. 2Department of Lab Hematology, All India Institute of Medical Sciences, New Delhi, India. 3Department of Pediatric Hemato Oncology, Sir Gangaram Hospital, New Delhi, India.

Correspondence to:*Jyoti Kotwal
drjyotikotwal@gmail.com

Part of the of data was presented as a poster at a national conference in 2022.

Received: October 21, 2023; Accepted: April 1, 2024

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Abstract

Background Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by reduced factor VIII (FVIII) levels. Approximately 10–15% of patients with severe HA (SHA) do not present with the anticipated bleeding pattern. Here, we assessed the phenotypic severity of hemophilia A using rotational thromboelastometry (ROTEM) and activated partial thromboplastin time-clot waveform analysis (APTT-CWA).
Methods Patients diagnosed with hemophilia A were enrolled. Clinical phenotype assignment was performed according to the published literature, and patients were classified into four phenotypic subgroups. The whole blood sample was first run on ROTEM in INTEM mode using platelet-poor plasma, APTT was run, and the APTT-CWA graph was simultaneously recorded.
Results A total of 66 patients were recruited for this study. Statistically significant differences were observed between the four phenotypically categorized groups using ROTEM and APTT-CWA. On comparing patients with mild/moderate-to-severe phenotypes (Group II) with SHA without inhibitors (Group IV), no significant difference was found for all parameters of ROTEM or APTT-CWA. The MCF, MA30, MAXV, and Alpha angle values using ROTEM were found to be the lowest in patients with SHA with inhibitors, which helped differentiate them from those with SHA without inhibitors. However, these two groups could not be differentiated using the APTT-CWA parameters.
Conclusion ROTEM can be used to distinguish patients with SHA with inhibitors from those with SHA without inhibitors using a combination of parameters with high sensitivity and specificity. However, APTT-CWA cannot be used to differentiate these patient groups.

Keywords: Hemophilia A, ROTEM, APTT-CWA , Phenotype severity, Bleeding disorder, Bethesda assay

Fig 1.

Figure 1.Temograms of the study population in Group I, Group II, Group III, and Group IV

Fig 2.

Figure 2.ROC curve analysis to calculate CT, CFT (A), MCF, and alpha angle (B) value for predicting mild/moderate hemophilia A with severe phenotype when compared to severe hemophilia A with inhibitors with severe phenotype (Group II vs. Group III)

Baseline characteristics of patients with HA according to severity determined by a one-stage FVIII assay.


CharacterMild HA (n = 13) median (range)Moderate HA (n = 18) median (range)Severe HA (n = 35) median (range)
Age in years (median & range)21 (5–57)7 (1–20)8 (0.5–47)
Age at diagnosis in years (median & range)5 (0.1–36)2 (0.1–12)0.6 (0.2–20)
Bleeding
Spontaneous/trauma joint bleeding [n (%)]4 (30.7)8 (44.4)34 (97.1)
ICH [n (%)]1 (7.6)1 (5.5)7 (20)
Muscle bleeds [n (%)]03 (16.6)4 (11.4)
Surgical bleeding [n (%)]2 (15.3)2 (11.1)4 (11.4)
Mucosal bleeding [n (%)]2 (15.2)12 (66.6)30 (85.7)
No bleeding [n (%)]5 (38.46)1 (5.5)0
Factor VIII level (%)21.8 (5.70–29.8)3.35 (1.0–4.9)0.4 (0.0–0.9)
Median (range)
Bleeding severity as per Shima et al. [18]
Severe (n)2435
Non-severe (n)11140


Distribution of clot waveform parameters between severe and non-severe HA and intergroup comparison between the phenotypic groups.


ParametersSevere HA (SHA) [N = 30] median (range)Non-Severe HA (non-SHA) [N = 24] median (range)P-value
1st derivative38.7 (15.62–134.6)116.3 (32.62–399.3)< 0.0001
2nd derivative42.1 (10–385.2)227.4 (28.62–1238.5)< 0.0001
Max213.95 (3.12–123.3)56.0 (7.7–529.8)< 0.0001
Group I (n = 25)Group II (n = 6)Group III (n = 14)Group IV (n = 21)P-value
1st derivative132.05 (46.7–399.3)70.45 (32.6–84.9)36.35 (15.6–70.3)47.25 (24.4–134.6)< 0.0001
2nd derivative271.0 (39.6–1238.5)97.5 (28.62–126.3)36.75 (10–105.9)49.05 (16.7–385.2)< 0.0001
Max263.3 (7.72–529.8)30.75 (11.1–58.6)11.0 (3.1–25)16.25 (3.8–123.3)< 0.0001
GROUPS1st derivative
P-value
2nd derivative
P-value
MAX2
P-value
Group I vs. II0.0010.0040.025
Group I vs. III< 0.0001< 0.0001< 0.0002
Group I vs. IV< 0.0001< 0.00010.001
Group II vs. III0.0220.0220.011
Group II vs. IV0.4440.3120.274
Group III vs. IV0.1080.1380.108


Distribution of ROTEM parameters between severe and non-severe HA and intergroup comparison between the phenotypic groups.


ROTEM (INTEM)Severe HA (n = 35) median (range)Non-severe HA (n = 31) median (range)P-value
CT727.0 (251–1852)343.0 (202–1084)< 0.0001
CFT184.0 (69–1904)76.0 (38–271)< 0.0001
MCF64.0 (27–81)68.0 (47–82)0.016
ALPHA ANGLE59.0 (0–76)75.0 (46–83)< 0.0001
MA3064.0 (19–82)68.0 (46–82)0.015
MAXV9.0 (2–37)17.0 (6–39)0.00001
MAXVT (seconds)852.0 (283–1952)368.0 (252–1299)0.00001
Group I (n = 25)Group II (n = 6)Group III (n = 14)Group IV (n = 21)P-value
CT310.0 (202–1084)542.0 (360–916)816.0 (502–1852)705.0 (251–1141)< 0.0001
CFT74.0 (38–271)120.5 (58–223)451.0 (122–1904)137.0 (69–241)< 0.0001
MCF68.0 (47–82)64.5 (52–82)53.5 (27–81)66.0 (54–72)0.019
α ANGLE75.0 (46–82)68.0 (51–83)41.5 (0–71)64.0 (48–76)< 0.0001
MA3068.0 (46–82)64.0 (52–82)44.0 (19–81)67.0 (54–75)0.0044
MAXV17 (6.0–39)14.5 (6.0–37)5 (2–16)10 (2.0–20)< 0.0001
MAX VT368.0 (252–1299)645.0 (384–1011)877.0 (760–1952)883.0 (282–1339)< 0.0001

Blood Res
Volume 60 2025

Supplementary File

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download